Key result
Lipoprotein(a) above 125 nmol/L affects roughly 1 in 5 adults and causally increases cardiovascular risk, though the first targeted outcome trial (Lp(a)HORIZON with pelacarsen) did not meet its primary endpoint.
Why the study?
Lipoprotein(a) independently raises cardiovascular risk in roughly one in five adults, requiring a synthesis of settled evidence and open questions now that the first targeted outcome trial has reported.
Does targeted or indirect lowering of elevated lipoprotein(a) reduce major cardiovascular events in adults with elevated lipoprotein(a)?
Does targeted or indirect lowering of elevated lipoprotein(a) reduce major cardiovascular events in adults with elevated lipoprotein(a)?
Answers are grounded in this paper and cite their sources.
This clinical review synthesizes evidence establishing lipoprotein(a) as a continuous, causal cardiovascular risk factor and provides a practical stepwise management algorithm focusing on intensive LDL-C lowering and PCSK9 inhibitors following the announcement that the first targeted outcome trial (Lp(a)HORIZON with pelacarsen) did not meet its primary endpoint.
Lipoprotein(a) [Lp(a)] is a genetically determined, low-density lipoprotein-like particle that raises the risk of myocardial infarction, large-artery ischaemic stroke and calcific aortic stenosis independently of LDL cholesterol. Roughly one adult in five has a concentration above 125 nmol/L (50 mg/dL), the threshold at which most guidance now labels risk as high. This review synthesises, for the general physician, what is settled and what remains open now that the first outcome trial of targeted Lp(a) lowering has reported. Mendelian randomisation and prospective cohorts, including the UK Biobank, the Copenhagen studies and the 30-year Women's Health Study, establish a continuous, causal and additive relation with cardiovascular events that persists at low achieved LDL cholesterol. Because concentration is stable, a single molar (nmol/L) measurement suffices for most adults, with repeat testing reserved for postmenopausal women and borderline values that would change a decision. Existing management is indirect: intensive LDL-cholesterol lowering, PCSK9 inhibitors (which lower Lp(a) by about a quarter), individualised aspirin decisions and lipoprotein apheresis for progressive disease. Antisense (pelacarsen) and small interfering RNA (olpasiran, lepodisiran, zerlasiran) agents and the oral inhibitor muvalaplin lower Lp(a) by 80% or more in phase 2 trials. However, on 4 September 2026 the first outcome trial, Lp(a)HORIZON (pelacarsen), was announced not to have met its primary endpoint; its full results and the small interfering RNA outcome trials are awaited. We propose explicit thresholds, an absolute-risk framing and a stepwise algorithm that can be applied now and refined as outcome data are published.
No takes yet. Share an insight, caveat, or question.
Dongol et al. (2026) conducted a review in Elevated lipoprotein(a) [Lp(a)] and atherosclerotic cardiovascular disease risk. Lipoprotein(a) measurement, intensive LDL-C lowering (statins, PCSK9 inhibitors), lipoprotein apheresis, and targeted Lp(a)-lowering agents (pelacarsen, olpasiran, lepodisiran, zerlasiran, muvalaplin) was evaluated on Major cardiovascular events (myocardial infarction, large-artery ischaemic stroke, calcific aortic stenosis, coronary revascularisation, and cardiovascular death). Lipoprotein(a) above 125 nmol/L affects roughly 1 in 5 adults and causally increases cardiovascular risk, though the first targeted outcome trial (Lp(a)HORIZON with pelacarsen) did not meet its primary endpoint.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: